Literature DB >> 1679950

Relationships between medication treatments and neuropsychological test performance in schizophrenia.

J A Sweeney1, J G Keilp, G L Haas, J Hill, P J Weiden.   

Abstract

Few investigations have assessed the neuropsychological effects of psychotropic medications on schizophrenic patients. In this study, 44 clinically stable schizophrenic inpatients were administered a battery of neuropsychological tests, and their performance was correlated with dosage of neuroleptic medication and benztropine. Neuroleptic dose was correlated with poorer performance on tests of psychomotor speed and attention, and with the number of perserverative errors on the Wisconsin Card Sort. Anticholinergic dose was associated with poorer verbal learning, verbal fluency, and motor speed. Both medication dosages were associated with poorer verbal recognition memory, but this association was strongly influenced by the performance of individuals on the highest medication doses. The findings, which were independent of clinical state and intelligence, indicate that higher doses of neuroleptic and anticholinergic medications are associated with poorer neuropsychological functioning in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679950     DOI: 10.1016/0165-1781(91)90065-w

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  13 in total

1.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

2.  Impact of antipsychotic treatment on attention and motor learning systems in first-episode schizophrenia.

Authors:  Sarah K Keedy; James L Reilly; Jeffrey R Bishop; Peter J Weiden; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-06-03       Impact factor: 9.306

3.  Deviation from expected cognitive ability across psychotic disorders.

Authors:  W C Hochberger; T Combs; J L Reilly; J R Bishop; R S E Keefe; B A Clementz; M S Keshavan; G D Pearlson; C A Tamminga; S K Hill; J A Sweeney
Journal:  Schizophr Res       Date:  2017-05-22       Impact factor: 4.939

4.  Cognitive burden of anticholinergic medications in psychotic disorders.

Authors:  Seenae Eum; S Kristian Hill; Leah H Rubin; Ryan M Carnahan; James L Reilly; Elena I Ivleva; Sarah K Keedy; Carol A Tamminga; Godfrey D Pearlson; Brett A Clementz; Elliot S Gershon; Matcheri S Keshavan; Richard S E Keefe; John A Sweeney; Jeffrey R Bishop
Journal:  Schizophr Res       Date:  2017-04-06       Impact factor: 4.939

5.  Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders.

Authors:  Lusi Zhang; Scot Kristian Hill; Bin Guo; Baolin Wu; Ney Alliey-Rodriguez; Seenae Eum; Paulo Lizano; Elena I Ivleva; James L Reilly; Richard S E Keefe; Sarah K Keedy; Carol A Tamminga; Godfrey D Pearlson; Brett A Clementz; Matcheri S Keshavan; Elliot S Gershon; John A Sweeney; Jeffrey R Bishop
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-10-29       Impact factor: 5.067

6.  Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia.

Authors:  Jessica A Wojtalik; Shaun M Eack; Bruce G Pollock; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2012-11-15       Impact factor: 3.222

7.  Pharmacokinetic patterns of risperidone-associated adverse drug reactions.

Authors:  Georgios Schoretsanitis; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Koen R J Schruers; Sebastian Walther; Sarah E Lammertz; Ekkehard Haen; Michael Paulzen
Journal:  Eur J Clin Pharmacol       Date:  2016-07-04       Impact factor: 2.953

8.  Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy.

Authors:  Robert O Cotes; David R Goldsmith; Sarah L Kopelovich; Cathy A Lally; Benjamin G Druss
Journal:  Community Ment Health J       Date:  2017-11-10

9.  Effects of word frequency on semantic memory in schizophrenia: electrophysiological evidence for a deficit in linguistic access.

Authors:  Ruth Condray; Greg J Siegle; Matcheri S Keshavan; Stuart R Steinhauer
Journal:  Int J Psychophysiol       Date:  2009-11-05       Impact factor: 2.903

10.  Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.

Authors:  Seenae Eum; S Kristian Hill; Ney Alliey-Rodriguez; James M Stevenson; Leah H Rubin; Adam M Lee; Lauren J Mills; James L Reilly; Rebekka Lencer; Sarah K Keedy; Elena Ivleva; Richard S E Keefe; Godfrey D Pearlson; Brett A Clementz; Carol A Tamminga; Matcheri S Keshavan; Elliot S Gershon; John A Sweeney; Jeffrey R Bishop
Journal:  Neuropsychopharmacology       Date:  2021-06-18       Impact factor: 8.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.